The document discusses resources, activities, and costs for biotech startups. It emphasizes that physical facilities create no value, while activities through true partners can generate data to drive value. Intellectual property is only valuable if it can improve patient outcomes, and there are few early-stage assets with compelling pre-clinical data demonstrating disease-modifying potential. The goal should be to produce the highest quality asset by bringing together resources and operational insights to avoid obstacles and drive the program toward an IND candidate. Metrics must be understood from the start and constantly reviewed to show whether the approach can modify disease and benchmark against competing programs.